Sign in
CompletedNo phase

Patterns and Glycaemic Endpoints for Diagnosing Gestational Diabetes

Key facts

Who runs it
Portsmouth Hospitals NHS Trust
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
180 people enrolled
Started
22 Nov 2023
Ended
8 May 2026
Type of study
Observational
Treatments tested
  • Libre 3 continuous glucose monitoring sensor
Record updated
17 September 2026

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Female aged 18 years of above
  • Between 12-26 weeks gestation
  • Identified by NICE as having one or more independent risk factor for GDM
  • Suitable for the standard care pathway under the joint antenatal clinic for GDM
  • Willing and able to give informed consent

Who cannot take part

  • Previous GDM
  • Pre-existing diabetes
  • Known allergy to freestyle libre adhesive pad
  • Participating in a different study that could interfere with glucose levels or affect ability to participate
  • Unsuitable for standard joint antenatal clinic pathway
  • Planning to move geographical area during the study timeframe

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Gestational diabetes (GDM) develops during pregnancy and is becoming increasingly common. The condition is associated with adverse outcomes for mother and baby during both the pregnancy and delivery period. This study compares glucose variability (recorded by a continuous glucose monitoring (CGM) sensor) in pregnant women who have been diagnosed with GDM with pregnant woman who do not have the diagnosis but are at high risk. The sensors will be applied to 400 participants around the time of their standard test for GDM, with a randomly selected 60 of these patients forming a sub-group later in the study to assess for progression of high blood glucose. At present, a positive oral glucose tolerance test (OGTT) is used to confirm the diagnosis of GDM but the test can be unreliable leading to potential diagnostic error. CGM devices are used extensively in the management of Type 1 diabetes and GDM, and have also shown potential to be used in the diagnosis of Type 2 diabetes.

Read full original descriptionShow less

If this study can demonstrate similar trends in glucose variability between OGTT positive patients and those who are OGTT negative but are at high risk for the condition, then further research into the utility of CGM as a diagnostic alternative or supplement to the OGTT would be indicated.

The investigators will recruit 400 patients at high risk for GDM, give them a blinded CGM device, and compare the CGM glucose data with their OGTT result, their initial risk factors for GDM, their pregnancy outcome and their need for treatment. The investigators will use the data to test our hypothesis that a positive OGTT result does not predict hyperglycaemia in pregnancy.

Treatments tested

  • Libre 3 continuous glucose monitoring sensor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Insights Into Glucose Variability Using Continuous Glucose Monitoring in Mothers With Gestational Diabetes Compared to Mothers at High Risk of Gestational Diabetes Who Have a Negative Oral Glucose Tolerance Test.
Record updated
17 September 2026